Real-World Effectiveness of Mavacamten in Canada
NCT06338202 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 115
Last updated 2025-12-04
Summary
The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM) in Canada.
Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
- DRUG
-
As detailed in the product label
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-06-24
- Primary Completion
- 2024-11-12
- Completion
- 2024-12-19
- FDA Drug
- Yes
Countries
- Canada
Study Locations
More Related Trials
-
Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy
NCT06947590 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
NCT06023186 ·Status: RECRUITING
-
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
NCT07107373 ·Status: ACTIVE_NOT_RECRUITING
-
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
NCT07103655 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
NCT07004972 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT03442764 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT03470545 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
NCT05414175 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
NCT03496168 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
NCT05489705 ·Status: RECRUITING
-
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
NCT05135871 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
NCT04766892 ·Status: COMPLETED ·Phase: PHASE2
-
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
NCT06551129 ·Status: RECRUITING
-
COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
NCT06372457 ·Status: ACTIVE_NOT_RECRUITING
-
Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy
NCT04164732 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
NCT03759392 ·Status: COMPLETED ·Phase: PHASE3
-
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
NCT07120776 ·Status: RECRUITING ·Phase: NA
-
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
NCT06081894 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
NCT03153137 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart Failure
NCT04434170 ·Status: COMPLETED
-
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
NCT02929329 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
NCT03153111 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
NCT01150461 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
The Effects of Sacubitril/Valsartan on the Heart Functions
NCT03830814 ·Status: COMPLETED